This review is part of a study for the Dutch Health Care Insurance Council to develop a generic method for examining combinations of medications. The study uses the RAND Appropriateness Method to determine where clinical research on pharmaceutical combinations is needed by evaluating the existing published evidence and clinical expertise about the use of these combinations. This generic method is to be pilot-tested by addressing the problem of prioritizing clinical research on combination medications for rheumatoid arthritis.
Note: this study is part of a larger RAND Europe study that is also available online. Please see related link.
This report is part of the RAND Corporation RAND Europe document series. RAND Europe reports (RE) were monograph/reports (MR) produced by RAND Europe. REs were published at RAND from 1998 to 2001. RAND monograph/reports presented major research findings that addressed the challenges facing the public and private sectors.
Permission is given to duplicate this electronic document for personal use only, as long as it is unaltered and complete. Copies may not be duplicated for commercial purposes. Unauthorized posting of RAND PDFs to a non-RAND Web site is prohibited. RAND PDFs are protected under copyright law. For information on reprint and linking permissions, please visit the RAND Permissions page.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.